Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Prima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Young water professionals take a closer look at food manufacturing
Olives used to predict oil quality before extraction
Scanning providers unite to help accelerate shift to next-gen barcodes
Six on the shelf: on-the-go protein, ready-to-cook veggies and more
What can food manufacturers learn from viral food trends?
Victoria announces "massive" upgrade to one of its busiest hospitals
NSW IRC decision prompts "mixed emotions" from nurses and midwives
Surgical robot expands its scope of procedures
Neuroscientists propose clinical definition for brain fog in menopause
National Pain Alliance launched to advocate for chronic pain
Manufacturing-friendly plastic surface destroys viruses on contact
Queensland Government reports progress on Energy Roadmap after six months
Government fast-tracks funding to support industry and shore up supply chains
AI won’t restart your plant: Why practical skills matter more than ever
POSCO Holdings steps up HILT CRC partnership